BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22733501)

  • 1. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?
    Potocki M; Ziller R; Mueller C
    Curr Heart Fail Rep; 2012 Sep; 9(3):244-51. PubMed ID: 22733501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
    Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin.
    Peacock WF
    Clin Chem Lab Med; 2014 Oct; 52(10):1433-5. PubMed ID: 24756062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
    Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
    Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
    ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction.
    Klip IT; Voors AA; Anker SD; Hillege HL; Struck J; Squire I; van Veldhuisen DJ; Dickstein K;
    Heart; 2011 Jun; 97(11):892-8. PubMed ID: 21415071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
    Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
    Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
    Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
    Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
    Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
    Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
    Brouwers FP; de Boer RA; van der Harst P; Struck J; de Jong PE; de Zeeuw D; Gans RO; Gansevoort RT; Hillege HL; van Gilst WH; Bakker SJ
    Heart; 2012 Sep; 98(18):1348-53. PubMed ID: 22821276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel predictive role for mid-regional proadrenomedullin in moderate to severe aortic stenosis.
    Tan ESJ; Oon YY; Chan SP; Liew OW; Chong JPC; Tay E; Soo WM; Yip JWL; Gong L; Lunaria JB; Yong QW; Lee EM; Yeo DPS; Ding ZP; Tang HC; Ewe SH; Chin CCW; Chai SC; Goh PP; Ling LF; Ong HY; Richards AM; Ling LH
    Heart; 2022 Jul; 108(16):1319-1327. PubMed ID: 35332049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
    Kuan WS; Ibrahim I; Chan SP; Li Z; Liew OW; Frampton C; Troughton R; Pemberton CJ; Chong JPC; Tan LL; Lin W; Ooi SBS; Richards AM
    Eur J Heart Fail; 2020 Apr; 22(4):692-700. PubMed ID: 31808279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and diagnostics in heart failure.
    Gaggin HK; Januzzi JL
    Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry.
    Špinarová M; Špinar J; Špinarová L; Krejčí J; Goldbergová-Pávková M; Pařenica J; Ludka O; Málek F; Ošťádal P; Benešová K; Jarkovský J; Lábr K
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.